MX2022012945A - Composición y método para el tratamiento de la leucemia oral. - Google Patents
Composición y método para el tratamiento de la leucemia oral.Info
- Publication number
- MX2022012945A MX2022012945A MX2022012945A MX2022012945A MX2022012945A MX 2022012945 A MX2022012945 A MX 2022012945A MX 2022012945 A MX2022012945 A MX 2022012945A MX 2022012945 A MX2022012945 A MX 2022012945A MX 2022012945 A MX2022012945 A MX 2022012945A
- Authority
- MX
- Mexico
- Prior art keywords
- mammalian subject
- pharmaceutically acceptable
- cytotoxic agent
- anticancer
- dispersed
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000001093 anti-cancer Effects 0.000 abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 239000002254 cytotoxic agent Substances 0.000 abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002489 hematologic effect Effects 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 108010032595 Antibody Binding Sites Proteins 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un método de tratamiento de un sujeto mamífero que tiene células cancerosas no tumorales hematológicas. El método comprende los pasos de: (A) administrarle al sujeto mamífero una cantidad terapéuticamente efectiva de un xanteno halogenado, una sal o éster de alquilo de 1 a 4 átomos de carbono farmacéuticamente aceptable del mismo, como un primer agente citotóxico contra el cáncer disuelto o disperso en un medio acuoso farmacéuticamente aceptable. El sujeto mamífero es mantenido por un período suficiente para inducir la muerte de las células de cáncer no tumorales hematológicas. La administración contemplada en la presente por lo general es repetida. El método de tratamiento contemplado en la presente también se puede realizar en conjunto con la administración, al sujeto mamífero, de una segunda cantidad terapéuticamente efectiva de un segundo agente citotóxico con diferente acción contra el cáncer, disuelto o disperso en un medio farmacéuticamente aceptable. El segundo agente citotóxico contra el cáncer puede ser una molécula pequeña o un anticuerpo intacto o una porción que contiene paratopos del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/027702 WO2022220841A1 (en) | 2021-04-16 | 2021-04-16 | Composition and method for oral treatment of leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012945A true MX2022012945A (es) | 2023-03-16 |
Family
ID=83640921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012945A MX2022012945A (es) | 2021-04-16 | 2021-04-16 | Composición y método para el tratamiento de la leucemia oral. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4117668A4 (es) |
| JP (1) | JP2023529262A (es) |
| KR (1) | KR20230171854A (es) |
| CN (1) | CN115955969A (es) |
| AU (1) | AU2021440597A1 (es) |
| CA (1) | CA3175637A1 (es) |
| MX (1) | MX2022012945A (es) |
| WO (1) | WO2022220841A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| KR20070022308A (ko) * | 2004-05-10 | 2007-02-26 | 로버트 에프 호프만 | 암 치료용 약제학적 조성물 |
| CN102482347B (zh) * | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| WO2018047917A1 (ja) * | 2016-09-09 | 2018-03-15 | 国立大学法人 東京大学 | Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 |
| JP2020516649A (ja) * | 2017-04-12 | 2020-06-11 | オーラ バイオサイエンシーズ， インコーポレイテッド | 標的化併用療法 |
| WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN112996502B (zh) * | 2018-05-16 | 2023-10-31 | 普罗维克图斯药品技术公司 | 卤代呫吨针对难治性小儿实体瘤的体外和异种移植抗肿瘤活性 |
-
2021
- 2021-04-16 AU AU2021440597A patent/AU2021440597A1/en active Pending
- 2021-04-16 CN CN202180038959.2A patent/CN115955969A/zh active Pending
- 2021-04-16 JP JP2022562946A patent/JP2023529262A/ja active Pending
- 2021-04-16 WO PCT/US2021/027702 patent/WO2022220841A1/en unknown
- 2021-04-16 CA CA3175637A patent/CA3175637A1/en active Pending
- 2021-04-16 EP EP21935450.3A patent/EP4117668A4/en active Pending
- 2021-04-16 KR KR1020227039851A patent/KR20230171854A/ko active Search and Examination
- 2021-04-16 MX MX2022012945A patent/MX2022012945A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023529262A (ja) | 2023-07-10 |
| AU2021440597A1 (en) | 2022-11-10 |
| KR20230171854A (ko) | 2023-12-21 |
| EP4117668A4 (en) | 2023-12-06 |
| WO2022220841A1 (en) | 2022-10-20 |
| EP4117668A1 (en) | 2023-01-18 |
| CN115955969A (zh) | 2023-04-11 |
| CA3175637A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| BR112021000724A2 (pt) | Composições e métodos para tratar os olhos | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| CA2402539A1 (en) | Combination therapies with vascular damaging activity | |
| Soloviev et al. | Mechanisms of vascular dysfunction evoked by ionizing radiation and possible targets for its pharmacological correction | |
| Floersheim et al. | Protection against ionising radiation and synergism with thiols by zinc aspartate | |
| BR112021001092A2 (pt) | composições e métodos para tratar os olhos | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| AU2022246418B2 (en) | Compositions and methods for treating the eye | |
| BR0012442A (pt) | Medicamento com ação protetora contra substâncias oxidantes tóxicas e particularmente contra substâncias cardiotóxicas | |
| AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| MX2022012945A (es) | Composición y método para el tratamiento de la leucemia oral. | |
| AR122341A1 (es) | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) | |
| EP0469064B1 (en) | Use of c-20 to c-26 aliphatic alcohols for the manufacture of a medicament for the treatment of viral infections | |
| US20230102836A1 (en) | Amoebicidal Compositions for Contact Lens Solutions | |
| BR112021001339A2 (pt) | composições e métodos para tratar os olhos | |
| BR112023022788A2 (pt) | Conjugado anticorpo-fármaco, fármaco-ligante, composição farmacêutica, uso do conjugado anticorpo-fármaco e método para tratar um câncer com alta expressão de ror1 | |
| JPH04506795A (ja) | 抗ウイルス治療におけるｃ―２７ないしｃ―３２脂肪族アルコールの使用 | |
| JP5499535B2 (ja) | 眼科用組成物及びなみだ目改善剤 | |
| MX2022005828A (es) | Composicion y metodo para tratamiento de canceres hematologicos. | |
| Alkhatib et al. | The apoptotic effect of gemcitabine-loaded-microemulsion (isopropyl myristate/tween 80/span 20/water/ethanol) on A549 non-small cell lung cancer cells | |
| Das | Radioprotection by superoxide dismutase | |
| Patrice et al. | Experimental aspects of in vitro and in vivo photochemotherapy |